Table 1 Eligibility criteria
Questions 1 and 2 (ASB screening) | Question 3 (ASB treatment) | |
|---|---|---|
Population | • Pregnant women taking part in routine maternal care • Without symptoms of UTI • With unknown ASB status | • Pregnant women with ASB detected in screening |
Study intervention | • Any ASB screening strategy followed by treatment, if necessary | • Any treatment for ASB |
Control intervention | • No ASB screening, but treatment if symptoms of UTI occur (question 1) • Any other ASB screening strategy followed by treatment, if necessary (question 2) | • No treatment or placebo |
Patient-relevant outcomes | • Pyelonephritis • UTI • Symptoms linked directly or indirectly to UTI (e. g. headache or visual impairment as symptoms of pre-eclampsia, fever) • Infant morbidity (e. g. respiratory distress syndrome, sepsis, cerebral haemorrhage, necrotising enterocolitis) • Perinatal mortality • Early preterm birth (< 32 weeks of gestation) • Very low birth weight (< 1500 g) • Health-related quality of life and psychosocial functioning • Any adverse event | |